Synopsis

Neoadjuvant chemotherapy is standard of care in women who are found to have clinical stage T2-4 N0 breast cancer or any T1-3 with HER2 positive breast cancer. Although ultrasound is frequently used in clinical settings MRI has been shown to be the most accurate technique in monitoring response and is used in measurement of initial volume and for assessing response. Residual disease can be over or underestimated in around 20% of cases. DWI and ADC are used in early measures of response as well as pharmacokinetic measurements such as ktrans.